Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

  1. Delforge, M.
  2. Otero, P.R.
  3. Shah, N.
  4. Moshkovich, O.
  5. Braverman, J.
  6. Dhanda, D.S.
  7. Lanar, S.
  8. Devlen, J.
  9. Miera, M.
  10. Gerould, H.
  11. Campbell, T.B.
  12. Munshi, N.C.
Revista:
Leukemia Research

ISSN: 1873-5835,  0145-2126

Any de publicació: 2023

Volum: 129

Tipus: Article

DOI: 10.1016/J.LEUKRES.2023.107074 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus